Photo I Courtesy of Insulet
Amit Guliani
March 19, 2025
Insulet’s first chief technology officer leaves company
Photo | Courtesy of Insulet
Mark Field
Just shy of two years after a C-suite reorganization at Insulet, Mark Field has left his position as the inaugural chief technology officer at the Acton medical device manufacturer.
Field, who also served as the firm’s senior vice president, stepped away from his positions on Friday to pursue other opportunities, according to a Monday filing with the U.S. Securities and Exchange Commission.
"During his six years at Insulet, Mark helped strengthen the Technology Organization and build a talented team that is essential in supporting our strategy and goals. To facilitate this transition, we plan to enter into a Consulting Agreement with Mark," Insulet said in an email to WBJ.
Field was immediately succeeded in an interim capacity by Amit Guliani, Insulet’s group vice president of software engineering Guliani will serve as acting chief technology officer while Insulet initiates a search for Field’s permanent replacement.
"Amit is a proven leader with 25 years of experience managing global software engineering teams at multiple Fortune 500 companies. We are well positioned to continue to deliver on our key business objectives and will take the time we need to find the right individual for the job," said Insulet in the email.
Field joined Insulet in 2019 as group vice president, according to his LinkedIn profile. He assumed the company’s first chief technology officer position in 2023. Prior to Insulet, Field served in the same C-suite role at Thermo Fisher Scientific, a Waltham-based medical device company.
In October, Insulet received $1.92 million as part of a state tax incentive program to develop 110 manufacturing positions, including engineering and quality technician jobs and those in sales and marketing; research and development; and customer support.
In December, the firm was awarded $452 million in total damages after a federal jury found its South Korean-based competitor EOFlow guilty for misappropriating Insulet trade secrets.
EDITOR'S NOTE: This article has been updated to include statements from Insulet.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare and diversity, equity, and inclusion industries.
WBJ Web Partners
Most Recent
Most Recent
0 Comments